All In Biotech

NDA 017484 · Baxter Hlthcare

Dextrose 5% and Electrolyte No. 48 In Plastic Container

Dextrose, Magnesium Chloride, Potassium Chloride, Potassium Phosphate, Monobasic, Sodium Chloride, Sodium Lactate · Injection

Last checked: Nov 19, 2026Latest source record: Feb 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Feb 2, 1979

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

3

3 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 13, 2020.

INDICATIONS AND USAGE 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 1979 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; MAGNESIUM CHLORIDE 31MG/100ML; POTASSIUM CHLORIDE 141MG/100ML; POTASSIUM PHOSPHATE, MONOBASIC 20MG/100ML; SODIUM CHLORIDE 12MG/100ML; SODIUM LACTATE 260MG/100ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pneumonia2
  • capillary leak syndrome1
  • covid-191
  • febrile neutropenia1
  • respiratory failure1
  • sepsis1
  • septic shock1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20221
20231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.